Discovery & Translational Research

Our comprehensive portfolio of DNA, RNA and ctDNA tests and real-world data solutions can help your global therapy development programs reach patients faster with fewer costs


  • Discover new ways to stratify responders or gain early insights into treatment response with our ctDNA monitoring portfolio, including FoundationOne®Monitor
  • Identify and validate biomarkers, from common point mutations to complex gene-expression signatures using our comprehensive testing portfolio, now including broad RNA-sequencing with FoundationOne®RNA
  • Get answers to your research questions using our real-world data (RWD) portfolio, including the Flatiron Health – Foundation Medicine Clinico-Genomic Database (CGDB)
Image
GAIN MOLECULAR RESPONSE INSIGHTS WITH CHANGES IN CTDNA TUMOR FRACTION (TF)1,2

We have a portfolio of tests to help you gain early insights into treatment response and advance your translational research, including personalized monitoring with FoundationOne®Tracker3, our tissue-informed ctDNA monitoring test, or with FoundationOne®Monitor, our tissue-naïve test featuring ctDNA TF.4

Image
IDENTIFY GENE EXPRESSION SIGNATURES WITH FOUNDATIONONE®RNA

Identify relevant biomarkers with FoundationOne®RNA – including expanded capabilities to offer gene expression reporting of over 1,500 genes4,5 – and preserve tissue through our novel extraction method to obtain DNA and RNA from a single sample.

Image
DISCOVER NEW BIOMARKERS WITH OUR COMPREHENSIVE PORTFOLIO

Our portfolio of 300+ gene liquid and tissue NGS tests can provide deep discovery insight across simple and complex biomarkers on a platform with proven commercial utility and appeal.

Image
REAL-WORLD DATA (RWD) CAN HELP YOU FIND ANSWERS AS YOU NAVIGATE A RAPIDLY EVOLVING STANDARD OF CARE IN PRECISION ONCOLOGY
  • The Flatiron Health Foundation Medicine Clinico-Genomic Database (CGDB) is a unique, regulatory-ready data resource through a partnership with Flatiron Health, a leading provider of clinical data
  • CGDB contains data with scale and completeness from more than 100,000 patients, including our rich genomics data where every sample has been tested with comprehensive genomic profiling (CGP) and Flatiron Health’s clinical data from electronic medical records

We Have Even More to Offer

Learn more about our comprehensive genomic profiling tests or explore our solutions for clinical development and companion diagnostics (CDx) or access and commercialization.

1 Sweeney, C., et al. Cancer Res (2023) 83 (7_Supplement): 3362. https://doi.org/10.1158/1538-7445.AM2023-3362.

2 Tumor fraction is reported as a laboratory professional service, which has not been reviewed or approved by the FDA.

3 For Investigational Use Only. The performance characteristics of this product have not been established.

4 For research use only. Not for use in diagnostic procedures.

5 Data on file, Foundation Medicine, Inc., 2023.

Important Safety Information

Select

FoundationOne CDx

FoundationOne®CDx is a qualitative next-generation sequencing based in vitro diagnostic test for cancer patients with solid tumors and is for prescription use only. The test analyzes 324 genes as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For the complete label, including companion diagnostic indications and important risk information, please visit www.F1CDxLabel.com